Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?

Company Overview - SurModics (SRDX) shares have increased by approximately 6% over the past month, outperforming the S&P 500 index [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for SurModics have trended downward in the past month, with a consensus estimate shift of -2050% [2] VGM Scores - SurModics has a strong Growth Score of A but a low Momentum Score of F, and a Value Score of D, placing it in the bottom 40% for value investment strategy [3] - The aggregate VGM Score for SurModics is C, which is relevant for investors not focused on a single strategy [3] Outlook - The downward trend in estimates suggests a negative outlook for SurModics, reflected in its Zacks Rank of 4 (Sell) [4] - A below-average return is expected from the stock in the upcoming months [4] Industry Comparison - SurModics is part of the Zacks Medical - Products industry, where Boston Scientific (BSX) has seen a 1.3% gain over the past month [5] - Boston Scientific reported revenues of $4.66 billion for the last quarter, marking a year-over-year increase of +20.9% [5] - For the current quarter, Boston Scientific is projected to post earnings of $0.72 per share, reflecting a +16.1% change from the previous year [6] - Boston Scientific holds a Zacks Rank of 3 (Hold) based on estimate revisions [6]